- Home
- PBH vs SLNO Comparison
PBH vs SLNO Comparison
Compare PBH & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBH
- SLNO
- Stock Information
- Founded
- PBH 1996
- SLNO 1999
- Country
- PBH United States
- SLNO United States
- Employees
- PBH N/A
- SLNO N/A
- Industry
- PBH Biotechnology: Pharmaceutical Preparations
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PBH Health Care
- SLNO Health Care
- Exchange
- PBH Nasdaq
- SLNO Nasdaq
- Market Cap
- PBH 3.3B
- SLNO 3.8B
- IPO Year
- PBH 2005
- SLNO 2014
- Fundamental
- Price
- PBH $63.06
- SLNO $50.80
- Analyst Decision
- PBH Buy
- SLNO Strong Buy
- Analyst Count
- PBH 5
- SLNO 10
- Target Price
- PBH $94.00
- SLNO $112.50
- AVG Volume (30 Days)
- PBH 581.5K
- SLNO 1.7M
- Earning Date
- PBH 11-06-2025
- SLNO 11-05-2025
- Dividend Yield
- PBH N/A
- SLNO N/A
- EPS Growth
- PBH 4.18
- SLNO N/A
- EPS
- PBH 4.26
- SLNO N/A
- Revenue
- PBH $1,120,150,000.00
- SLNO $32,656,999.00
- Revenue This Year
- PBH N/A
- SLNO N/A
- Revenue Next Year
- PBH $2.24
- SLNO $175.39
- P/E Ratio
- PBH $14.66
- SLNO N/A
- Revenue Growth
- PBH 0.63
- SLNO N/A
- 52 Week Low
- PBH $61.93
- SLNO $41.50
- 52 Week High
- PBH $90.04
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- PBH 50.19
- SLNO 22.87
- Support Level
- PBH N/A
- SLNO $50.63
- Resistance Level
- PBH $66.04
- SLNO $72.99
- Average True Range (ATR)
- PBH 1.31
- SLNO 4.32
- MACD
- PBH -2.31
- SLNO -1.54
- Stochastic Oscillator
- PBH 91.86
- SLNO 7.08
About PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.